idarubicin has been researched along with MODS in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, B; Chen, D; Guan, C; Peng, M; Shao, X; Xie, P; Xu, P; Yuan, C | 1 |
| Aziz, A; Gosbell, IB; Sanghavi, R; Varghese, B | 1 |
2 other study(ies) available for idarubicin and MODS
| Article | Year |
|---|---|
Primary Philadelphia chromosome positive acute myeloid leukemia: A case report.
Topics: Antineoplastic Agents; Bone Marrow Examination; Cytarabine; Dasatinib; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Idarubicin; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multiple Organ Failure; Mutation; Philadelphia Chromosome | 2018 |
Toxic shock syndrome caused by hospital-acquired methicillin-resistant Staphylococcus aureus in a patient with pancytopenia.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cross Infection; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Methicillin-Resistant Staphylococcus aureus; Multiple Organ Failure; Pancytopenia; Shock, Septic; Staphylococcal Infections | 2010 |